Medication Monitor

Generic Name (Trade Name—Company)
May 1, 2011


(Tradjenta—Boehringer Ingelheim, Eli Lilly)
Treatment of type 2 diabetes


Treatment of adult patients with type 2 diabetes as an adjunct to diet and exercise

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has some unique features compared with other DPP-4 inhibitors on the market. It does not require dosage modifications in patients with renal impairment, it has a long terminal half-life (> 100 h), and it will only be marketed in a single strength of 5 mg for once-daily dosing. The efficacy and safety of linagliptin have been evaluated in numerous trials involving nearly 4,000 patients with type 2 diabetes, FDA said. When given as monotherapy, treatment with linagliptin resulted in glycosylated hemoglobin (A1C) reductions of up to 0.7% compared with placebo. When used in combination with other oral antidiabetic agents, the addition of linagliptin resulted in reductions in A1C levels of 0.5% to 0.6% compared with placebo. Nasopharyngitis was the most commonly reported adverse event with the drug.